| P50 | author | Reinhard Windhager | Q15842070 |
| | Margit Hemetsberger | Q56761037 |
| P2093 | author name string | Thomas Brodowicz | |
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | Giant cell tumour of bone: morphological, biological and histogenetical aspects | Q24595415 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. | Q30988491 |
| | Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? | Q33631210 |
| | Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors | Q33806271 |
| | Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group | Q33837310 |
| | Giant cell tumor of bone: risk factors for recurrence | Q34476929 |
| | Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. | Q35212194 |
| | Denosumab treatment for fibrous dysplasia | Q36040881 |
| | Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene | Q37265676 |
| | Noonan-like/multiple giant cell lesion syndrome | Q37314091 |
| | Effects of denosumab treatment and discontinuation on human growth plates | Q37616880 |
| | Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy | Q37955104 |
| | RANKL, denosumab, and giant cell tumor of bone. | Q38009727 |
| | An unusual giant cell tumor of the thyroid: case report and review of the literature | Q38060694 |
| | Giant cell tumor of bone: review, mimics, and new developments in treatment. | Q38074404 |
| | Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study | Q38448131 |
| | Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone | Q39092826 |
| | Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution | Q39867909 |
| | Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab | Q40713943 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours | Q42640096 |
| | Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. | Q42648818 |
| | Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study | Q42660832 |
| | Long-Term Renal Safety Profile of Ibandronate 6 mg Infused over 15 Minutes | Q42908723 |
| | Giant cell tumor of the sphenoid bone occurring during pregnancy: successful tumor extirpation via endoscopic transnasal transsphenoidal surgery | Q43568148 |
| | Denosumab dose selection for patients with bone metastases from solid tumors | Q45598335 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| | A system for the surgical staging of musculoskeletal sarcoma. 1980. | Q48679637 |
| | Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 |
| | Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. | Q51065526 |
| | Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. | Q51787826 |
| | A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab. | Q54195560 |
| | Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57570627 |
| | Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone | Q57570810 |
| | Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case–control study | Q58493695 |
| | Cytochemical and Ultrastructural Changes in the Osteoclast-like Giant Cells of Giant Cell Tumor of Bone Following Bisphosphonate Administration | Q58493724 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | giant cell tumor | Q18554961 |
| P304 | page(s) | 1881-1894 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Denosumab for the treatment of giant cell tumor of the bone | |
| P478 | volume | 11 | |